Radiation Therapy Exacerbates Tumor-Promoting Innervation and Nerve Signaling in Rectal Cancer.
Journal
International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
received:
11
05
2022
revised:
24
08
2022
accepted:
24
09
2022
pmc-release:
01
03
2024
pubmed:
7
10
2022
medline:
4
2
2023
entrez:
6
10
2022
Statut:
ppublish
Résumé
Many solid tumors present with perineural invasion (PNI), and innervation correlates with worsened prognosis. The effects that commonly administered therapies such as radiation therapy (RT) have on PNI status remain unknown. We investigated the contribution of RT on the nervous system and elucidated the implications that increased nerve signaling can have on tumor burden using our previously developed orthotopic murine model of rectal cancer (RC) and our targeted and clinically relevant short-course RT (SCRT) regimen. Medical charts for patients with RC treated at the Wilmot Cancer Institute were obtained and PNI status was analyzed. Human data were accompanied by an orthotopic murine model of RC. Briefly, luciferase-expressing murine colon-38 (MC38-luc) tumor cells were injected orthotopically into the rectal wall of C57BL6 mice. Targeted SCRT (5 gray (Gy) per fraction for 5 consecutive fractions) was administered to the tumor. Intratumoral innervation was determined by immunohistochemistry (IHC), local norepinephrine (NE) concentration was quantified by enzyme-linked immunosorbent assay (ELISA), and β2-adrenergic receptor (B2AR) expression was assessed by flow cytometry. Chronic NE signaling was mirrored by daily isoproterenol treatment, and the effect on tumor burden was determined by overall survival, presence of metastatic lesions, and tumor size. Isoproterenol signaling was inhibited by administration of propranolol. Human RC patients with PNI have decreased overall survival compared with patients without PNI. In our mouse model, SCRT induced the expression of genes involved in neurogenesis, increased local NE secretion, and upregulated B2AR expression. Treating mice with isoproterenol resulted in decreased overall survival, increased rate of metastasis, and reduced SCRT efficacy. Interestingly, the isoproterenol-induced decrease in SCRT efficacy could be abrogated by blocking the BAR through the use of propranolol, suggesting a direct role of BAR stimulation on impairing SCRT responses. Our results indicate that while SCRT is a valuable treatment, it is accompanied by adverse effects on the nervous system that may impede the efficacy of therapy and promote tumor burden. Therefore, we could speculate that therapies aimed at targeting this signaling cascade or impairing nerve growth in combination with SCRT may prove beneficial in future cancer treatment.
Identifiants
pubmed: 36202180
pii: S0360-3016(22)03415-0
doi: 10.1016/j.ijrobp.2022.09.080
pmc: PMC9898185
mid: NIHMS1858130
pii:
doi:
Substances chimiques
Isoproterenol
L628TT009W
Propranolol
9Y8NXQ24VQ
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
733-745Subventions
Organisme : NCI NIH HHS
ID : R01 CA230277
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA236390
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA262580
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
J Allergy Clin Immunol. 1980 Jan;65(1):29-33
pubmed: 6243144
Cancer. 2009 Aug 1;115(15):3379-91
pubmed: 19484787
FASEB J. 2000 Oct;14(13):2097-107
pubmed: 11023994
Medicine (Baltimore). 2015 Jul;94(27):e1097
pubmed: 26166098
Nat Commun. 2020 Apr 14;11(1):1821
pubmed: 32286326
Am J Surg Pathol. 2016 Jan;40(1):103-12
pubmed: 26426380
J Innate Immun. 2014;6(5):607-18
pubmed: 24642449
Br J Anaesth. 2018 Jul;121(1):45-57
pubmed: 29935594
Cancer. 2014 Apr 15;120(8):1178-86
pubmed: 24415516
BMB Rep. 2015 May;48(5):295-300
pubmed: 25748171
Science. 1988 Jan 1;239(4835):57-61
pubmed: 2447647
Prog Mol Biol Transl Sci. 2015;131:251-79
pubmed: 25744676
Lancet Oncol. 2017 Jun;18(6):e294
pubmed: 28593849
Am J Physiol Lung Cell Mol Physiol. 2006 Jul;291(1):L58-65
pubmed: 16443641
Science. 2013 Jul 12;341(6142):1236361
pubmed: 23846904
Eur J Immunol. 2016 Aug;46(8):1948-58
pubmed: 27222010
Adv Radiat Oncol. 2021 Dec 09;7(2):100867
pubmed: 35036637
Cancer Res. 2017 Oct 15;77(20):5639-5651
pubmed: 28819022
Surgery. 2000 Apr;127(4):412-8
pubmed: 10776432
Trends Immunol. 2003 Jun;24(6):302-6
pubmed: 12810105
Hypertension. 2004 Dec;44(6):897-902
pubmed: 15477382
Front Immunol. 2017 Feb 06;8:86
pubmed: 28220123
Oncotarget. 2016 Nov 22;7(47):77825-77837
pubmed: 27788481
Front Immunol. 2016 Dec 08;7:560
pubmed: 28008330
Int J Surg. 2018 Aug;56:195-202
pubmed: 29807169
Burns. 2004 Jun;30(4):317-21
pubmed: 15145188
Nature. 2011 Nov 20;480(7375):104-8
pubmed: 22101429
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3078-83
pubmed: 26929329
Surg Infect (Larchmt). 2012 Aug;13(4):187-93
pubmed: 22913335
Ann Surg. 1943 Jul;118(1):76-90
pubmed: 17858252
Cancer Res. 2010 Jan 1;70(1):68-77
pubmed: 20028852
Cancer Cell. 2017 Jan 9;31(1):21-34
pubmed: 27989802
Cureus. 2019 Dec 5;11(12):e6299
pubmed: 31938592
Cancer Res. 2008 Jan 15;68(2):346-51
pubmed: 18199526
J Gastrointest Oncol. 2019 Dec;10(6):1238-1250
pubmed: 31949945